GeoVax Labs, Inc. (GOVX.OB) Announces Encouraging HIV/AIDS Vaccine Trial Results
GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), today told the investment community of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine. According to the press release, this completed study represents the first HIV/AIDS vaccine trial to show prevention of infection. Robert McNally, Ph.D., Chief Executive Officer and President stated, "The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and…